GlassScriptPhysician profile
Jillian Adams
NPI 1033513031
$12,626.85
in general payments reported to CMS, 2019-2025
29 companies · $2,467 in 2025
The $2,467 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,257 · 2022: $2,951 · 2023: $2,851 · 2024: $3,101 · 2025: $2,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,407 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,406.98 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,142.41 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,432.31 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,357.40 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,111.64 | 2021-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $981.21 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $737.03 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $735.61 | 2022-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Janssen Pharmaceuticals, INC | $667.62 | 2021-2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $608.84 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $510.48 | 2021-2022 | |
| Corium, LLC | $373.43 | 2021-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $346.68 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $298.17 | 2022-2024 | Ingrezza |
| Noven Pharmaceuticals, INC. | $221.18 | 2023-2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $213.60 | 2025 | Jornay Pm |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $145.65 | 2021-2023 | Austedo Xr |
| Neuronetics, INC. | $134.42 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $117.60 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $116.77 | 2025 | Fanapt |
| Neos Therapeutics, LP | $106.10 | 2022-2023 | Cotempla Xr-Odt |
| Noven Therapeutics, LLC | $74.60 | 2023-2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $40.96 | 2022-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $32.84 | 2021-2022 | |
| Almatica Pharma LLC | $25.92 | 2022 | |
| Eisai INC. | $21.51 | 2022 | |
| Bausch Health US, LLC | $20.83 | 2023 | Aplenzin, Wellbutrin |
| Sage Therapeutics, LLC | $20.57 | 2025 | Zurzuvae |
| Aytu Biopharma, INC. | $18.79 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.